header.html

An official website of the European Union How do you know?      
European Commission logo

handle.jsp

cover
Background. With the increasing use of nanomaterials, the need for methods and assays to examine their immunosafety is becoming urgent, in particular for nanomaterials that are deliberately administered to human subjects (as in the case of nanomedicines). To obtain reliable results, standardised in vitro immunotoxicological tests should be used to determine the effects of engineered nanoparticles on the human immune responses. However, before assays can be standardised, it is important that suitable methods are established and validated. Results. In a collaborative work between European laboratories, existing immunological and toxicological in vitro assays were tested and compared for their suitability to test effects of in nanoparticles on -immune responsesotoxicological testing. The prototypical nanoparticles used were metal (oxide) particles, either custom-generated by wet synthesis or commercially available as powders. Several problems and challenges were encountered during assay validation, ranging from particle agglomeration in biological media and optical interference with assay systems, to chemical immunotoxicity of solvents and contamination with endotoxin.
2011-08-26
BIOMED CENTRAL LTD
JRC63262
1743-8977,   
http://www.particleandfibretoxicology.com/content/8/1/8,    https://publications.jrc.ec.europa.eu/repository/handle/JRC63262,   
10.1186/1743-8977-8-8,   
NameCountryCityType
Datasets
IDTitlePublic URL
Dataset collections
IDAcronymTitlePublic URL
Scripts / source codes
DescriptionPublic URL
Additional supporting files
File nameDescriptionFile type 

footer.html